Mairs & Power Inc’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Mairs & Power Inc’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,000	Closed	-$201K	–	225
2021 Q3	$201K	Hold	2,000	–	–	﹤0.01%	208
2021 Q2	$283K	Buy	+2,000	New	+$226K	﹤0.01%	186
2021 Q1	–	Sell	-2,000	Closed	-$247K	–	221
2020 Q4	$247K	Buy	+2,000	New	+$263K	﹤0.01%	201
2020 Q3	–	Sell	-2,000	Closed	-$312K	–	212
2020 Q2	$312K	Hold	2,000	–	–	﹤0.01%	176
2020 Q1	$289K	Hold	2,000	–	–	﹤0.01%	173
2019 Q4	$409K	Buy	+2,000	New	+$365K	﹤0.01%	170

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Mairs & Power Inc's RETA Position: Q4 2021 in Review

Mairs & Power Inc sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 2,000 shares — an estimated $201K sold.

Mairs & Power Inc first reported a position in RETA in Q4 2019 and held it in 6 quarters. The position peaked at $409K in Q4 2019. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Mairs & Power Inc reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Mairs & Power Inc sold 2,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $201K.
Mairs & Power Inc first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 6 quarters.
Mairs & Power Inc's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $409K in Q4 2019.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Mairs & Power Inc's 13F filing for Q4 2021, filed 14 Feb 2022.